Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Nurix Therapeutics (NRIX) Accumulated Depreciation & Amortization (2019 - 2025)

Nurix Therapeutics (NRIX) has disclosed Accumulated Depreciation & Amortization for 7 consecutive years, with $8.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Accumulated Depreciation & Amortization fell 6.2% to $8.7 million in Q4 2025 year-over-year; TTM through Nov 2025 was $8.7 million, a 6.2% decrease, with the full-year FY2025 number at $8.7 million, down 6.2% from a year prior.
  • Accumulated Depreciation & Amortization was $8.7 million for Q4 2025 at Nurix Therapeutics, down from $40.7 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $40.7 million in Q3 2025 to a low of $1.8 million in Q1 2023.
  • A 5-year average of $12.8 million and a median of $8.1 million in 2023 define the central range for Accumulated Depreciation & Amortization.
  • Peak YoY movement for Accumulated Depreciation & Amortization: tumbled 78.76% in 2021, then skyrocketed 89.29% in 2022.
  • Nurix Therapeutics' Accumulated Depreciation & Amortization stood at $2.8 million in 2021, then surged by 89.29% to $5.3 million in 2022, then surged by 42.13% to $7.5 million in 2023, then rose by 23.7% to $9.3 million in 2024, then dropped by 6.2% to $8.7 million in 2025.
  • Per Business Quant, the three most recent readings for NRIX's Accumulated Depreciation & Amortization are $8.7 million (Q4 2025), $40.7 million (Q3 2025), and $9.3 million (Q4 2024).